Is SELLAS Life Sciences Group, Inc. profitable?

SELLAS Life Sciences Group, Inc. is not currently profitable: it reported a net loss of $29.5M over the trailing twelve months, a -4130.1% net margin.

What are SELLAS Life Sciences Group, Inc.'s profit margins?

Gross margin is 90.0% and operating margin is -4195.0%, with a -4130.1% net margin.

What is SELLAS Life Sciences Group, Inc.'s earnings per share?

SELLAS Life Sciences Group, Inc.'s diluted EPS over the trailing twelve months is $-0.23.

Where does SELLAS Life Sciences Group, Inc.'s income statement data come from?

Every line is extracted from SELLAS Life Sciences Group, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

SELLAS Life Sciences Group, Inc. SLS Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Research and development	$16.02M-16.1%	$19.1M-20.5%	$24.01M+18.4%	$20.27M+29.3%
General and administrative	——	——	——	——
Total costs & expenses	$28.27M-10.3%	$31.51M-16.8%	$37.87M-11.8%	$42.95M+30.6%
Operating income	-$28.27M+10.3%	-$31.51M+16.8%	-$37.87M+9.7%	-$41.95M-65.8%
Other income (expense), net	$1.41M+123%	$632K+19.5%	$529K-18.5%	$649K-85.1%
Net income	-$26.86M+13.0%	-$30.88M+17.3%	-$37.34M+9.6%	-$41.3M-99.5%
Diluted earnings per share	-$0.25+51.9%	-$0.52+61.8%	-$1.36+39.0%	-$2.23-67.7%
Basic earnings per share	-$0.25+51.9%	-$0.52+61.8%	-$1.36+39.0%	-$2.23-67.7%
Weighted-average shares, diluted	403.8M+74.1%	231.9M+115%	108M+41.9%	76.1M+23.8%
Weighted-average shares, basic	403.8M+74.1%	231.9M+115%	108M+41.9%	76.1M+23.8%
Interest Income (Expense), Nonoperating	$1.41M+123%	$632K+20.4%	$525K—	——
Accounts payable	——	-$2.14M-193%	$2.3M+89.7%	$1.21M—
Accrued liabilities	——	——	$1.45M-60.3%	$3.65M+402%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	-$1.25M—
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	$86.3M+84.6%	$46.76M+109%	$22.34M-7.2%	$24.08M+99.4%
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	-$28.39M+19.8%	-$35.4M-12.7%	-$31.41M-31.9%	-$23.81M+8.5%
Research and development expense	$16.02M-16.1%	$19.1M-20.5%	$24.01M+18.4%	$20.27M+29.3%
Stock-based compensation	$1.96M+25.1%	$1.56M-25.3%	$2.09M+21.3%	$1.73M+70.7%
EBIT	-$28.27M+10.3%	-$31.51M+16.8%	-$37.87M+9.7%	-$41.95M-65.8%
EBITDA	——	——	——	——
EBIT	-$28.27M+10.3%	-$31.51M+16.8%	-$37.87M+9.7%	-$41.95M-65.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is SELLAS Life Sciences Group, Inc. profitable?: SELLAS Life Sciences Group, Inc. is not currently profitable: it reported a net loss of $29.5M over the trailing twelve months, a -4130.1% net margin.
What are SELLAS Life Sciences Group, Inc.'s profit margins?: Gross margin is 90.0% and operating margin is -4195.0%, with a -4130.1% net margin.
What is SELLAS Life Sciences Group, Inc.'s earnings per share?: SELLAS Life Sciences Group, Inc.'s diluted EPS over the trailing twelve months is $-0.23.
Where does SELLAS Life Sciences Group, Inc.'s income statement data come from?: Every line is extracted from SELLAS Life Sciences Group, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.